Compare Amphastar Pharmaceuticals Inc (AMPH) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Lamb Weston Holdings Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Lamb Weston Holdings Inc trades at $46.5 (market cap $6.41B). The key difference: Lamb Weston Holdings Inc is far larger — about 7.8× Amphastar Pharmaceuticals Inc's market cap, and Lamb Weston Holdings Inc pays a 3.27% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | LW | |
|---|---|---|
Market Cap | $826.08M | $6.41B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $66.57 |
52-Week Low | $16.87 | $38.48 |
Enterprise Value | $1.22B | $10.38B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Lamb Weston (LW) trades at $46.45, up 2.67% today, with a bullish technical signal and consistent earnings beats. The stock shows strong operational cash flow of $868.3M in 2025 and a P/E of 21.81, while recent news highlights its 'Focus to Win' strategy gaining traction. Support sits at $45 with resistance at $46.
Outlook remains positive with a $49.33 consensus price target, though net income declined to $357.2M in 2025. Risks include a pending class action lawsuit and margin pressures, but cost-saving initiatives and activist investor involvement support upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
